FDA Approves First Gene Therapy for Hemophilia A FDA Approves First Gene Therapy for Hemophilia A

Most patients benefit from valoctocogene roxaparvovec for at least 2 years, but it ' s not known how long the effect lasts.Medscape Medical News

Source: Medscape Hematology-Oncology Headlines - June 30, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news